2025 年 ASCO 大会正在召开中。本届大会上,乐普生物以LBA 口头报告的形式,首次披露了 EGFR ADC维贝柯妥塔单抗(MRG003)用于治疗晚期鼻咽癌(NPC)的 Ⅱb 期临床研究结果。截图来源:ASCO 官网维贝柯妥塔单抗是全球研发进度最快的 EGFR ADC,已在中国申报上市,并被纳入优先审评,用于既往经至少二线系统化疗和 PD-1/PD-L1 抑制剂治疗失败的复发/转移性鼻咽癌...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.